Table 1.
The demographic and baseline characteristics of the patients with Burkholderia capecia keratitis
| No. | Age/ sex |
Year | Risk factors | Prior use of cortico- steroid |
Location , size |
Hypopyon | Corneal perforation | Treatment | Surgery | Presenting VA |
Final VA |
Other isolates |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 71/f | 2003 | Diabetic mellitus | − | C, L | + | − | Ceftazidime, Vancomycin | − | NLP | NLP | |
| 2 | 52/m | 2007 | Ocular trauma | + | C, S | + | − | Ceftazidime, Sulfamethoxazole/Trimethoprim | AMT | CF | CF | Candida parapsilosis |
| 3 | 64/f | 2010 | Diabetic mellitus, Recent ocular surgery (PKP) | + | C, L | − | − | Ceftazidime | AMT, patch graft, evisceration | NLP | NLP | |
| 4 | 71/m | 2010 | HZV keratitis | − | C, L | − | + | Amikacin, Vancomycin, Sulfamethoxazole/Trimethoprim | − | NLP | NLP | Serratia marcescens |
| 5 | 24/m | 2010 | HSV keratitis | + | PC, L | − | − | Ceftazidime, acyclovir | − | CF | 20/200 | |
| 6 | 57/f | 2014 | HSV keratitis | − | C, L | − | + | Levofloxacin, acyclovir | Patch graft, PKP | HM | LP | |
| 7 | 85/m | 2016 | Unknown | − | C, L | + | − | Amikacin, voriconazole | − | HM | HM | Fusarium solani |
| 8 | 53/m | 2016 | Ocular trauma | + | PC, M | + | + | Ceftazidime, Moxifloxacin (oral), Vancomycin | 20/200 | 20/70 | ||
| 9 | 84/f | 2017 | Ocular surface problem | − | PC, S | − | − | Levofloxacin | − | CF | CF | |
| 10 | 50/f | 2017 | Contact lens wear | − | PC, S | − | − | Levofloxacin | − | 20/25 | 20/50 | |
| 11 | 88/f | 2017 | Recent ocular surgery (PKP, AMT) | + | C, M | + | − | Levofloxacin | AMT | HM | 20/1000 | Pseudomonas aeruginosa |
| 12 | 60/m | 2017 | Unknown | − | C, L | + | − | Levofloxacin | AMT, keratectomy, tarsorrhaphy, patch graft | CF | NA | |
| 13 | 84/f | 2018 | HSV keratitis | + | PC, S | + | + | Ceftazidime | − | HM | CF | |
| 14 | 65/f | 2018 | Diabetic mellitus, Recurrent ocular ulcer | + | PC, M | + | − | Levofloxacin | − | HM | NLP | Corynebacterium propinquum, Corynebacterium species |
| 15 | 48/m | 2018 | Ocular trauma | − | PC, S | − | − | Levofloxacin | − | 20/50 | 20/30 |
Bacillus megaterium, Arthrobacter species |
| 16 | 69/f | 2019 | Unknown | − | C, L | − | − | Levofloxacin | − | NLP | NLP | Pseudomonas aeruginosa |
| 17 | 36/m | 2019 | HZV keratitis, Contact lens wear | + | C, M | − | − | Levofloxacin | − | CF | 20/400 |
AMT amniotic membrane transplantation, C central, CF counting fingers, f female, HM hand motion, HSV herpes simplex virus, HZV herpes zoster virus, L large, LP light perception, m male, M medium, NA not available, NLP no light perception, PC paracentral, PKP penetrating keratoplasty, S small, VA visual acuity